Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Alpha-2 Agonist — Rosacea Erythema

Brimonidine Gel (Topical)

Brand names: Mirvaso

Brimonidine topical gel is an alpha-2 adrenergic agonist applied to the face to reduce the persistent facial erythema (redness) of rosacea.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

By stimulating alpha-2 adrenoceptors on cutaneous blood vessels it produces vasoconstriction of the dilated dermal vessels responsible for rosacea-associated redness.

Prescribing in practice

  • Some patients experience rebound or worsening erythema and flushing as the effect wears off, so a small test area and gradual introduction are advisable before regular facial use.
  • It treats redness only and has no effect on the inflammatory papules and pustules of rosacea, which need separate therapy.
  • Apply to intact skin only, avoiding the eyes, mouth and broken or irritated skin.

Monitoring

Review tolerability after initial use, watching specifically for rebound erythema, paradoxical flushing or contact irritation.

Counselling the patient

  • Apply a thin layer smoothly across the face once daily and wash your hands afterwards.
  • Be aware redness may sometimes return or worsen as the gel wears off; stop and seek advice if this is troublesome.

Evidence & guidelines

Efficacy for rosacea erythema is established in randomised controlled trials and reflected in the SPC.

Reference: Fowler et al. (2012) J Drugs Dermatol Brimonidine rosacea; BAD Rosacea Guidelines 2017; NICE CKS Rosacea; SPC Mirvaso; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways